Lab Requirements and Monitoring of Deucravacitinib Treatment
Dermatology physician assistants review the laboratory and monitoring requirements for TYK2 inhibitors deucravacitinib.
EP: 1.Overview of the Recent Development in the Treatment Landscape: Plaque Psoriasis
EP: 2.The Evolving Role of Advanced Practice Providers Treating Plaque Psoriasis
EP: 3.Plaque Psoriasis as a Systemic Disease
EP: 4.The Oral Systemic Space of Plaque Psoriasis
EP: 5.Lab Requirements and Monitoring of Deucravacitinib Treatment
EP: 6.Recent Long Term Clinical Trial Data on Deucravacitinib
EP: 7.Safety Data on Deucravacitinib
EP: 8.Impact of the Expanding Treatment Landscape on the Treatment Algorithm of Plaque Psoriasis
EP: 9.Good Candidates for TYK2 Inhibitors
EP: 10.Patient Experience With Oral Systemic Treatments
EP: 11.Selecting Appropriate Therapy in the Evolving Treatment Landscape of Plaque Psoriasis
Summary
In this series, dermatologists TJ Chao and Kristine Kucera delve into recent developments in plaque psoriasis treatment, including the emergence of TYK2 inhibitors. They highlight the evolving role of physician assistants in managing plaque psoriasis and discuss its recognition as a systemic disease. The conversation covers lab and monitoring requirements for TYK2 inhibitors like deucravacitinib, alongside a review of short- and long-term clinical trial data. Chao and Kucera offer insights into patient selection and the patient experience with oral systemic agents, providing guidance for selecting appropriate therapies in the expanding treatment landscape.
This summary was AI-generated and edited for clarity.
